Latest research on Ustekinumab

CNTO 1275 is the experimental name for the human immunosuppressive drug ustekinumab developed by the biotechnology company Centocor. It is a laboratory-manufactured, monoclonal antibody directed against interleukins IL-12 and IL-23 and presently undergoing clinical trials to determine its safety and effectiveness against the diseases Multiple Sclerosis, Psoriasis, and Psoriatic Arthritis.

Ustekinumab interactions

Thus, the objectives of this study were to assess patient-reported treatment satisfaction and patient-reported choice of dosing frequency options among patients with moderate to severe psoriasis and treated with a subcutaneous injectable biologic (adalimumab, etanercept, or Ustekinumab) or a non-biologic (Cyclosporine or methotrexate) medication. [source, 2015]
We used an administrative health care claims database to identify patients who were taking a subcutaneous injectable biologic (adalimumab, etanercept, or Ustekinumab), methotrexate, or Cyclosporine for the treatment of moderate to severe plaque psoriasis and to obtain demographic and clinical data. [source, 2015]
Patients were included if they met all of the following criteria: at least one claim with a diagnosis of psoriasis (ICD-9-CM 696.1) in any position within the identification period;26 at least one claim for methotrexate, Cyclosporine, or an injectable biologic (adalimumab, etanercept, or Ustekinumab) prescription for treatment of psoriasis within the identification period or 1 year prior to the first diagnosis of psoriasis during the identification period; age 18 years or older; willingness to sign and return the informed consent and health information release forms; and a patient-confirmed diagnosis of psoriasis. [source, 2015]
Medical claims included diagnosis of psoriasis (ICD-9-CM 696.1); and pharmacy claims for methotrexate, Cyclosporine, or a subcutaneous injectable biologic agent (adalimumab, etanercept, Ustekinumab). [source, 2015]
Patient characteristics obtained from the survey included weight (in lbs at time of survey); years since diagnosis; self-reported disease severity (number of patient handprint-sized areas covered converted into percentage of skin affected and labeled into categories “very mild”, “mild”, “moderate”, “severe”, and “extremely severe”); self-reported health status (“excellent”, “very good”, “good”, “fair”, and “poor”); and current treatment regimen (methotrexate, Cyclosporine, adalimumab, etanercept, or Ustekinumab). [source, 2015]
It is believed that EAC represents a cutaneous manifestation of a type IV hypersensitivity reaction to different causes and underlying systemic diseases, including: food Allergy, arthropod bites, drug reactions (Finasteride, Chloroquine, hydroxyChloroquine, Hydrochlorothiazide, Piroxicam, etizolam, cimetidine, penicillin, salicylates, Spironolactone, Gold sodium thiomalate, Amitriptyline, Ustekinumab, rituximab), infections disease (bacterial, viral, parasitic, fungal, mycobacterial), endocrine and immunological disorders (menstrual cycle, Graves disease, Hashimoto thyroiditis, Sjögren syndrome, autoimmune progesterone dermatitis), hematological and other neoplastic disorders (Hodgkin lymphoma, non-Hodgkin lymphoma, acute leukemia, histiocytosis, multiple myeloma, nasopharyngeal carcinoma, prostatic adenocarcinoma, breast carcinoma, ovarian carcinoma) [5–10]. [source, 2015]
The following were considered as treatments: methotrexate, cyclosporine and Acitretin categorized as classical systemic drugs; and infliximab, etanercept, adalimumab and Ustekinumab categorized as biological drugs. [source, 2015]
The primary outcome was Ustekinumab clinical benefit at 3 months, defined by a significant improvement as judged by the physician leading to continue the treatment with Complete steroids weaning if given at inclusion. [source, 2015]
However, the case reported of successful treatment of acrodermatitis of Hallopeau, a severe and often refractory form of pustular psoriasis affecting distal fingers and toes, required co-therapy with Acitretin and higher than standard doses of Ustekinumab in order to achieve Complete clinical resolution [151]. [source, 2015]
In accordance with the existing guidelines, systemic agents, such as the conventional therapies (Cyclosporine, methotrexate, retinoids, and phototherapy) and the biologic agents, including the tumor necrosis factor (TNF) antagonists (adalimumab, etanercept, and infliximab), as well as the interleukin 12/23 antagonist Ustekinumab, are recommended for the treatment of moderate to severe PP. [source, 2015]